These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12811513)

  • 21. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
    Carmichael J; Allerheiligen S; Walling J
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):55-9. PubMed ID: 8893883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
    Ng EW; Sandler AB; Robinson L; Einhorn LH
    Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Mikhaeel-Kamel N; Pan Z; Murphy J; Prindiville S; Bunn PA
    Clin Cancer Res; 2000 Sep; 6(9):3474-9. PubMed ID: 10999731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
    Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
    J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
    du Bois A; Belau A; Wagner U; Pfisterer J; Schmalfeldt B; Richter B; Staehle A; Jackisch C; Lueck HJ; Schroeder W; Burges A; Olbricht S; Elser G;
    Gynecol Oncol; 2005 Feb; 96(2):444-51. PubMed ID: 15661234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
    Edelman MJ; Gandara DR; Lau DH; Lara P; Lauder IJ; Tracy D
    Cancer; 2001 Jul; 92(1):146-52. PubMed ID: 11443620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
    Dudek AZ; Larson T; Keshtgarpour M; Kumar P
    Am J Clin Oncol; 2007 Oct; 30(5):481-6. PubMed ID: 17921707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
    Grivas PD; Hussain M; Hafez K; Daignault-Newton S; Wood D; Lee CT; Weizer A; Montie JE; Hollenbeck B; Montgomery JS; Alva A; Smith DC
    Urology; 2013 Jul; 82(1):111-7. PubMed ID: 23706253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
    Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
    Lim N; Lara PN; Lau DH; Edelman MJ; Tanaka M; al-Jazayrly G; Houston J; Lauder I; Gandara DR
    Cancer Invest; 2003; 21(1):7-13. PubMed ID: 12643004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
    Bhatia S; Hanna N; Ansari R; Pletcher W; Einhorn L; Ng E; Sandler A
    Lung Cancer; 2002 Oct; 38(1):73-7. PubMed ID: 12367796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
    Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
    Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
    Pectasides D; Aspropotamitis A; Halikia A; Visvikis A; Antoniou F; Kalantaridou A; Karvounis N; Batzios S; Athanassiou A
    J Clin Oncol; 1999 Dec; 17(12):3816-21. PubMed ID: 10577854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
    Hussain M; Vaishampayan U; Du W; Redman B; Smith DC
    J Clin Oncol; 2001 May; 19(9):2527-33. PubMed ID: 11331332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
    Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
    J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
    Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
    Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
    Treat JA; Gonin R; Socinski MA; Edelman MJ; Catalano RB; Marinucci DM; Ansari R; Gillenwater HH; Rowland KM; Comis RL; Obasaju CK; Belani CP;
    Ann Oncol; 2010 Mar; 21(3):540-547. PubMed ID: 19833819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.